Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
Issues
2016
June 2016, Vol 7, No 5
June 2016, Vol 7, No 5
Nivolumab Monotherapy Prolongs Survival in Patients with Advanced Melanoma
By
Wayne Kuznar
Melanoma
,
Solid Tumors
June 2016, Vol 7, No 5
More than 33% of patients with heavily pretreated advanced melanoma are still alive at 5 years after starting nivolumab (Opdivo) monotherapy, reported F. Stephen Hodi, Jr, MD, Director of the Melanoma Center, Dana-Farber Cancer Institute, Boston, at the 2016 American Association for Cancer Research (AACR) meeting.
Read Article
Debating the Role of Intralesional Therapy in Melanoma
By
Walter Alexander
Melanoma
,
Solid Tumors
June 2016, Vol 7, No 5
“Intralesional therapy is here to stay,” said Sanjiv S. Agarwala, MD, Section Chief, Hematology/Oncology, St Luke’s University Health Network, Easton, PA, who moderated a debate on this topic at the recent
HemOnc Today
Melanoma and Cutaneous Malignancies meeting.
Read Article
Telehealth Applications in Patient Care
By
F. Randy Vogenberg, PhD, RPh, FASHP
Employers’ Perspective
,
Value Peer-spectives
June 2016, Vol 7, No 5
The term telehealth is used interchangeably with telemedicine by some organizations. However, telemedicine is typically associated with the delivery of traditional clinical diagnosis and monitoring by using some form of medical technology, whereas telehealth has a much broader definition that comprises education, disease awareness, and wellness, in addition to the use of technology to connect physicians to patients.
Read Article
Real-World Data Show 2-Year Survival Predicts Long-Term Survival for Metastatic Germ-Cell Testicular Cancer
By
Phoebe Starr
Genitourinary Cancers
June 2016, Vol 7, No 5
Contemporary treatment has led to improvements in survival for all patients with metastatic testicular germ-cell tumors (GCTs), including poor-risk patients, although they still have worse survival. A new study shows that if poor-risk patients receive curative therapy and survive for at least 2 years, their survival approaches that of favorable-risk and intermediate-risk patients. The study supports no further routine scanning 2 years after diagnosis in surviving patients.
Read Article
Opioid Use Decreases in Gynecologic Cancer Surgery with Liposomal Bupivacaine
By
Charles Bankhead
Gynecologic Cancer
June 2016, Vol 7, No 5
Read Article
Slow Uptake of Minimally Invasive Surgery for Endometrial Cancer
By
Charles Bankhead
Gynecologic Cancer
June 2016, Vol 7, No 5
More than 50% of women with early-stage endometrial cancer had open surgery, in contradiction to recommendations in clinical guidelines, according to a study reported at the 2016 Society of Gynecologic Oncology (SGO) annual meeting.
Read Article
Minor Changes in Systemic Therapy Recommendations in NCCN Breast Cancer Guideline
By
Wayne Kuznar
Breast Cancer
,
Solid Tumors
June 2016, Vol 7, No 5
Read Article
Early Results of Immunotherapy in Breast Cancer
By
Phoebe Starr
Breast Cancer
,
Solid Tumors
June 2016, Vol 7, No 5
Read Article
Novel Regimen Outperforms Standard Chemotherapy in HER2 Breast Cancer
By
Charles Bankhead
Breast Cancer
,
Solid Tumors
June 2016, Vol 7, No 5
An ongoing clinical trial of a novel strategy to evaluate new chemotherapy regimens for patients with early-stage breast cancer has identified another neoadjuvant combination therapy worthy of a phase 3 clinical trial involving patients with HER2-positive breast cancer.
Read Article
Approval of First Liquid Biopsy to Detect EGFR Mutations in Lung Cancer Can Improve Patient Outcomes
By
Jessica Miller
Lung Cancer
,
Solid Tumors
June 2016, Vol 7, No 5
The first liquid biopsy used to detect gene mutations that are associated with non–small-cell lung cancer (NSCLC) was approved by the FDA. The cobas EGFR Mutation Test v2 (Roche Molecular Systems), a blood-based companion diagnostic for erlotinib (Tarceva), is indicated as an initial test to detect
EGFR
gene mutations in patients with NSCLC.
Read Article
Page 1 of 3
1
2
3
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Navigating the Complex Landscape of Oral Cancer Medication
2.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
3.
New NCCN Guidelines for CLL/SLL Include Second-Generation BTK Inhibitors
Wayne Kuznar
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma